
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1011 | 1010 | 1129 | 841 | 1095 | 1248 |
Fund Return | 1.14% | 1.03% | 12.94% | -5.59% | 1.82% | 2.24% |
Place in category | 394 | 249 | 339 | 119 | 163 | 51 |
% in Category | 59 | 40 | 55 | 30 | 62 | 70 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Morgan Stanley HX Health Industry | 1.75B | -1.58 | -15.83 | - | ||
Morgan Stanley Huaxin Multiple Fact | 583.16M | 2.21 | -5.12 | 4.17 | ||
MS Huaxin Resource Selected Mixed | 417.95M | 0.58 | -14.15 | 2.66 | ||
MS Huaxin Aggressive Growth Equity | 346.35M | 2.39 | -9.07 | 4.98 | ||
Huaxin Leading Advanced Stock | 316.65M | 6.01 | -6.14 | 7.62 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Zhong Ou Modern Pioneer InitiatingA | 11.32B | 2.97 | -8.18 | - | ||
TianHong ChiNext Index A | 9.8B | 1.24 | -7.98 | - | ||
TianHong ChiNext Index C | 9.8B | 1.20 | -8.16 | - | ||
ICBC Credit Literary Ids Eq | 5.6B | 7.24 | -1.38 | - | ||
Harvest Emerging Industry Eq | 5.17B | 1.68 | -10.08 | 10.23 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Amperex Tech A | CNE100003662 | 5.83 | 249.06 | -1.53% | |
Midea Group A | CNE100001QQ5 | 4.26 | 75.39 | -3.96% | |
Wuliangye A | CNE000000VQ8 | 2.58 | 131.79 | +0.33% | |
Boe Technology A | CNE0000016L5 | 2.52 | 4.20 | +1.20% | |
BYD A | CNE100001526 | 2.21 | 365.50 | -2.51% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Sell | Buy | Buy |
Technical Indicators | Strong Sell | Strong Buy | Strong Buy |
Summary | Strong Sell | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review